Oncotarget

Research Papers:

Phospholipase Cδ1 suppresses cell migration and invasion of breast cancer cells by modulating KIF3A-mediated ERK1/2/β- catenin/MMP7 signalling

Qing Shao, Xinrong Luo, Dejuan Yang, Can Wang, Qiao Cheng, Tingxiu Xiang _ and Guosheng Ren

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:29056-29066. https://doi.org/10.18632/oncotarget.16072

Metrics: PDF 1021 views  |   HTML 1629 views  |   ?  


Abstract

Qing Shao1,*, Xinrong Luo1,2,*, Dejuan Yang1, Can Wang1, Qiao Cheng1,2, Tingxiu Xiang1, Guosheng Ren1,2

1Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

2Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

*These authors have contributed equally to this work

Correspondence to:

Tingxiu Xiang, email: larissaxiang@163.com

Guosheng Ren, email: rengs726@126.com

Keywords: PLCD1, tumour suppressor, breast cancer, KIF3A, MMP7

Received: December 15, 2016    Accepted: February 20, 2017    Published: March 10, 2017

ABSTRACT

Phospholipase C δ1 (PLCD1) encodes an enzyme involved in energy metabolism, calcium homeostasis and intracellular movement. It is located at 3p22 in a region that is frequently deleted in multiple cancers, and the PLCD1 enzyme is a potential tumour suppressor in breast cancer that inhibits matrix metalloprotease (MMP) 7, but the detailed mechanism remains elusive. In this study, we found that PLCD1 was downregulated in breast cancers, and the gain-or-loss functional assay revealed that PLCD1 inhibited cell migration and invasion in vitro via the ERK1/2/β-catenin/MMP7 signalling pathway. Furthermore, KIF3A was identified as a downstream mediator of PLCD1, and there was an inverse correlation between the expression of PLCD1 and KIF3A. Knockdown of KIF3A expression alone suppressed cell migration and invasion, and attenuated ERK1/2/β-catenin/MMP7 signalling that was reactivated by knocking down PLCD1 in vitro. Collectively, our findings suggest that PLCD1 acts as a tumour suppressor, by KIF3A-mediated suppression of ERK1/2/β-catenin/MMP7 signalling, at least in part, in breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16072